Temporal trends indicate an epidemiological shift in the pathology of mesial temporal lobe epilepsy

Christoph Helmstaedter1, Sarah Al-Haj Mustafa2, Juri-Alexander Witt2

  • 1Department of Epileptology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. Christoph.Helmstaedter@ukbonn.de.

Journal of Neurology
|September 24, 2025
PubMed
Abstract

Insights

Mesial temporal lobe epilepsy (mTLE) shows an epidemiological shift, with fewer early-onset cases and more late-onset suspected limbic encephalitis (sLE) cases. This suggests changing causes and clinical features in mTLE patients over time.

Area of Science:

  • Neurology
  • Epileptology
  • Neuroscience

Background:

  • Recent studies indicate a decline in early-onset mesial temporal lobe epilepsy with ammon's horn sclerosis (mTLE-AHS).
  • Simultaneously, there's a growing recognition of late-onset mTLE associated with suspected limbic encephalitis (sLE).
  • An epidemiological shift in mTLE patient demographics is hypothesized.

Purpose of the Study:

  • To analyze temporal trends in a large cohort of mTLE patients over four decades.
  • To evaluate changes in age, onset, clinical presentation, and MRI pathology.
  • To investigate the shift from mTLE-AHS to sLE.

Main Methods:

  • Retrospective analysis of 1,556 anonymized mTLE patient records from 1986-2024.
  • Evaluation of temporal trends in age, epilepsy onset, neuropsychological performance, and MRI findings.
  • Data analyzed in five-year intervals.

Main Results:

  • A significant trend of increasing age at epilepsy onset (12 to 36 years) was observed.
  • Education and IQ increased, while impairments became less global and memory deficits less pronounced.
  • Early-onset mTLE-AHS decreased from 100% to 32%, while late-onset sLE increased from 0% to 68%.

Conclusions:

  • The changing etiologies and clinical features of mTLE suggest a significant epidemiological shift.
  • The decline in mTLE-AHS and rise in sLE necessitate further investigation into underlying factors.
  • Prospective studies on autoantibody subgroups in sLE are recommended.